Tech Company Financing Transactions
ORIC Pharmaceuticals Funding Round
EcoR1 Capital Management, Foresite Capital and OrbiMed joined a $53 million Series B venture round for ORIC Pharmaceuticals. The round was recorded on 12/3/2015.
Transaction Overview
Company Name
Announced On
12/3/2015
Transaction Type
Venture Equity
Amount
$53,000,000
Round
Series B
Investors
Proceeds Purpose
The funds will be used to support advancement of the company's first drug candidate into initial clinical trials and to further develop the company's pipeline.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
240 E. Grand Ave. 2nd Floor
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
ORIC Pharmaceuticals Nasdaq: ORIC) is dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to current drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jacob Chacko
Chief Financial Officer
Dominic Piscitelli
Chief Medical Officer
Pratik Multani
Chief Scientific Officer
Lori Friedman
Vice President
Edna Maneval
VP - Bus. Development
Matthew Panuwat
VP - General Counsel
Christian Kuhlen
Browse more venture capital transactions:
Prev: 12/3/2015: Figma venture capital transaction
Next: 12/4/2015: Icon Bioscience venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs